Provided by Tiger Fintech (Singapore) Pte. Ltd.

Humacyte, Inc.

2.90
-0.1900-6.15%
Post-market: 2.960.0600+2.07%16:22 EDT
Volume:2.17M
Turnover:6.32M
Market Cap:373.14M
PE:-2.14
High:3.04
Open:3.03
Low:2.84
Close:3.09
Loading ...

Humacyte rises 6% as regulators reviewing bioengineered human tissue asset

seekingalpha
·
09 Nov 2024

Humacyte Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
09 Nov 2024

Stock Track | Humacyte Stock Surges Despite Wider Q3 Losses, Investors Await Outlook

Stock Track
·
08 Nov 2024

Stock Track | Humacyte Shares Plunge as Q3 Earnings Miss Estimates

Stock Track
·
08 Nov 2024

Humacyte GAAP EPS of -$0.33 misses by $0.08

seekingalpha
·
08 Nov 2024

Humacyte Q3 2024 GAAP EPS $(0.33) Misses $(0.25) Estimate. Cash and Equivalents of $71M

Benzinga
·
08 Nov 2024

Stock Track | Humacyte Reports Wider Q3 Loss, Pre-Market Stock Surges

Stock Track
·
08 Nov 2024

BRIEF-Humacyte Q3 Operating Expenses USD 30.233 Million

Reuters
·
08 Nov 2024

Humacyte Q3 Operating Income USD -30.233 Million VS. Ibes Estimate USD -29.7 Million

THOMSON REUTERS
·
08 Nov 2024

Humacyte Q3 Basic EPS USD -0.33

THOMSON REUTERS
·
08 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 Nov 2024

Humacyte Q3 2024 Earnings Preview

seekingalpha
·
08 Nov 2024

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

GlobeNewswire
·
06 Nov 2024

Humacyte Inc : H.c. Wainwright Raises Target Price to $12 From $6

THOMSON REUTERS
·
05 Nov 2024

Humacyte price target raised to $12 from $6 at H.C. Wainwright

TIPRANKS
·
05 Nov 2024

BRIEF-Humacyte Announces Presentation Of Positive Results From V007 Phase 3 Av Access Clinical Trial At The American Society Of Nephrology’S Kidney Week 2024

Reuters
·
28 Oct 2024